281 related articles for article (PubMed ID: 28652016)
1. Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism.
Wang L; Baser O; Wells P; Peacock WF; Coleman CI; Fermann GJ; Schein J; Crivera C
Clin Ther; 2017 Jul; 39(7):1426-1436.e2. PubMed ID: 28652016
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care.
Peacock WF; Coleman CI; Wells P; Fermann GJ; Wang L; Baser O; Schein J; Crivera C
J Health Econ Outcomes Res; 2019; 6(3):160-173. PubMed ID: 32685588
[TBL] [Abstract][Full Text] [Related]
3. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
[TBL] [Abstract][Full Text] [Related]
4. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism.
Coleman CI; Baugh C; Crivera C; Milentijevic D; Wang SW; Lu L; Nelson WW
J Med Econ; 2017 Feb; 20(2):200-203. PubMed ID: 27780397
[TBL] [Abstract][Full Text] [Related]
5. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status.
Weeda ER; Peacock WF; Fermann GJ; Baugh CW; Wells PS; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
Int J Clin Pract; 2017 Jan; 71(1):. PubMed ID: 28097761
[TBL] [Abstract][Full Text] [Related]
6. Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?
Coleman CI; Fermann GJ; Weeda ER; Wells PS; Ashton V; Crivera C; Bunz TJ; Wildgoose P; Schein JR; Peacock WF
Clin Appl Thromb Hemost; 2017 Oct; 23(7):830-837. PubMed ID: 27481875
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With Warfarin.
Margolis JM; Deitelzweig S; Kline J; Tran O; Smith DM; Crivera C; Bookhart B; Schein J
Clin Ther; 2016 Nov; 38(11):2496-2503. PubMed ID: 27751675
[TBL] [Abstract][Full Text] [Related]
8. Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin.
Weeda ER; Wells PS; Peacock WF; Fermann GJ; Baugh CW; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
Intern Emerg Med; 2017 Apr; 12(3):311-318. PubMed ID: 27757790
[TBL] [Abstract][Full Text] [Related]
9. Cost of Treating Venous Thromboembolism With Heparin and Warfarin Versus Home Treatment With Rivaroxaban.
Kahler ZP; Beam DM; Kline JA
Acad Emerg Med; 2015 Jul; 22(7):796-802. PubMed ID: 26111453
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism.
Weeda ER; Kohn CG; Peacock WF; Fermann GJ; Crivera C; Schein JR; Coleman CI
Pharmacotherapy; 2016 Oct; 36(10):1109-1115. PubMed ID: 27548074
[TBL] [Abstract][Full Text] [Related]
11. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
[TBL] [Abstract][Full Text] [Related]
12. Benefit of early discharge among patients with low-risk pulmonary embolism.
Wang L; Baser O; Wells P; Peacock WF; Coleman CI; Fermann GJ; Schein J; Crivera C
PLoS One; 2017; 12(10):e0185022. PubMed ID: 29016692
[TBL] [Abstract][Full Text] [Related]
13. Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs.
Spyropoulos AC; Ashton V; Chen YW; Wu B; Peterson ED
Thromb Res; 2019 Oct; 182():159-166. PubMed ID: 31493618
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.
Peterson ED; Ashton V; Chen YW; Wu B; Spyropoulos AC
Am Heart J; 2019 Jun; 212():113-119. PubMed ID: 30981035
[TBL] [Abstract][Full Text] [Related]
16. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
[TBL] [Abstract][Full Text] [Related]
17. Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
Laliberté F; Cloutier M; Crivera C; Nelson WW; Olson WH; Schein J; Vanderpoel J; Germain G; Lefebvre P
Adv Ther; 2015 Mar; 32(3):216-27. PubMed ID: 25784509
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
19. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
Fung KP; Chan KH; Ng V; Tsui PT; You JHS
Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal evaluation of health plan cost per venous thromboembolism or bleed event in patients with a prior venous thromboembolism event during hospitalization.
Bullano MF; Willey V; Hauch O; Wygant G; Spyropoulos AC; Hoffman L
J Manag Care Pharm; 2005 Oct; 11(8):663-73. PubMed ID: 16194130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
